Menu Search

Peter Mannon

peter.mannon@unmc.edu

402-559-6209

Dr. Mannon's translational research in IBD has focused on improving current treatment responses by studying endophenotypes of disease to predict efficacy of approaches and testing novel, or re-purposing existing, drugs for inflammatory bowel disease (IBD). An overarching point of reference for his research program is the gap between response and non-response to conventional and experimental treatments. This perspective has allowed Dr. Mannon and his collaborators to show how IL-10 production and infiltration of the lamina propria with suppressor-inducing plasmacytoid dendritic cells conferred clinical response from G-CSF therapy in Crohn’s disease (while non-responders showed neither finding) and also how high IL-17 production could prevent (predict) lack of clinical response to interferon-beta in ulcerative colitis (UC).  Current research projects are focused on defining endophenotypes of IBD that can predict enhanced responses to highly targeted therapeutic agents, specifically anti-IL-13, anti-IL-17, and anti-TNFa in treating UC as well as identifying the microbial-antigen reactivity of highly shared TCRβ CDR3 clonotypes in Crohn’s disease which has become the basis for a long-term project to develop T cell-based immunotherapies for Crohn’s disease.

Dr. Mannon has served as the GI Site expert on the Human Microbiome Project, involved in the early stages of protocol planning and at the final stages of data analysis. His expertise in this area supported projects on the role of gut microbiome in solid organ transplant-associated metabolic syndrome and microbiome effects on Barretts esophagus.  He has significant experience in designing and executing investigator-initiated studies as well as sponsored studies.  He has extensive experience in translational research in inflammatory bowel disease and mucosal immunology, and specific experience in the role of biologic agents in gut epithelial and mucosal immune response as well as a specific interest in the mechanism of inflammation in IBD. 

Featured Publications

Morgan N, Mannon PJ.  Flagellin-specific CD4 cytokine production in Crohn's disease and controls is limited to a small subset of antigen-induced CD40L+ T cells. J Immunol. 2020 (in press)

Peter S, Pendergraft A, VanDerPol W, Wilcox CM, Kyanam Kabir Baig KR, Morrow C, Izard J, Mannon PJ.  Mucosa-Associated Microbiota in Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma Differ Similarly Compared With Healthy Controls.  Clin Transl Gastroenterol. 2020 Aug;11(8)

Mannon PJ. Systemic antibody responses to gut commensal bacteria: How and why do I know you? J Allergy Clin Immunol. 2019 Apr;143(4):1353-1354

Wu J, Pendegraft AH, Byrne-Steele M, Yang Q, Wang C, Pan W, Lucious T, Seay T, Cui X, Elson CO, Han J, Mannon PJ. Expanded TCRβ CDR3 clonotypes distinguish Crohn's disease and ulcerative colitis patients. Mucosal Immunol. 2018 Sep;11(5):1487-1495

Brant SR, Okou DT, Simpson CL, Cutler DJ, Haritunians T, Bradfield JP, Chopra P, Prince J, Begum F, Kumar A, Huang C, Venkateswaran S, Datta LW, Wei Z, Thomas K, Herrinton LJ, Klapproth JA, Quiros AJ, Seminerio J, Liu Z, Alexander JS, Baldassano RN, Dudley-Brown S, Cross RK, Dassopoulos T, Denson LA, Dhere TA, Dryden GW, Hanson JS, Hou JK, Hussain SZ, Hyams JS, Isaacs KL, Kader H, Kappelman MD, Katz J, Kellermayer R, Kirschner BS, Kuemmerle JF, Kwon JH, Lazarev M, Li E, Mack D, Mannon P, Moulton DE, Newberry RD, Osuntokun BO, Patel AS, Saeed SA, Targan SR, Valentine JF, Wang MH, Zonca M, Rioux JD, Duerr RH, Silverberg MS, Cho JH, Hakonarson H, Zwick ME, McGovern DP, Kugathasan S. Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease. Gastroenterology. 2017 Jan;152(1):206-217